Anne Gitte Rasmussen Loft

Impact of different infliximab dose regimens on treatment response and drug survival in 462 patients with psoriatic arthritis: results from the nationwide registries DANBIO and ICEBIO

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Bente Glintborg, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Bjorn Gudbjornsson, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Niels Steen Krogh, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Emina Omerovic, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Natalia Manilo, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Mette Holland-Fischer, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Hanne M Lindegaard, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Anne Gitte Loft
  • Henrik Nordin, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Laura Johnsen, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Sussi Flejsborg Oeftiger, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Annette Hansen, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Claus Rasmussen, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Gerdur Grondal, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Arni Jon Geirsson, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an
  • ,
  • Merete Lund Hetland, Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Danish Rheumatologic Database (DANBIO), Glostrup Hospital, Glostrup, Denmark, Center for Rheumatology Research (ICEBIO), Landspitali University Hospital of Iceland, Faculty of Medicine, University of Iceland, Reykjavik, Iceland, Zitelab Aps, Department of Rheumatology, Frederiksberg Hospital, Copenhagen, Department of Rheumatology, Aalborg University Hospital, Aalborg, Department of Rheumatology, Odense University Hospital, Odense, Department of Rheumatology, Vejle Sygehus, Sygehus Lillebælt, Department of Infectious Diseases and Rheumatology, Rigshospitalet, Copenhagen, Department of Rheumatology, Helsingør and Hillerød Hospital, Hillerød, Department of Rheumatology, Køge Hospital, Køge, Department of Rheumatology, Gentofte University Hospital, Copenhagen, Department of Rheumatology, Vendsyssel Teaching Hospital, Hjørring, Denmark, Department of Rheumatology, Landspitali University Hospital of Iceland, Reykjavik, Iceland an

OBJECTIVE: The aim of this study was to describe dose regimens, dose escalation and clinical outcomes in TNF-α inhibitor (TNFi)-naive patients with PsA treated with infliximab in routine rheumatology care.

METHODS: We conducted an observational cohort study based on the nationwide Danish Rheumatologic Database (DANBIO) and Center for Rheumatology Research (ICEBIO) registries. Stratified by country, characteristics of patients treated with ≤3 mg infliximab/kg body weight, 3-5 mg/kg or ≥5 mg/kg every 8 weeks were described. Outcomes were evaluated by ACR 20%, 50% and 70% (ACR20/50/70) responses and European League Against Rheumatism good response after 6 months, disease activity after 12 months, Kaplan-Meier plots and regression analyses.

RESULTS: Four hundred and sixty-two patients (376 Danish, 86 Icelandic) received treatment with infliximab. In Danish patients, the starting dose was ≤3 mg/kg in 110 patients (29%), 3-5 mg/kg in 157 (42%), ≥5 mg/kg in 38 (10%) and unregistered in 71 (19%). In Icelandic patients, corresponding numbers were 64 (74%), 17 (27%), 0 (0%) and 5 (6%). Patients with a higher body weight received lower doses per kilogram. Danish patients received higher doses than Icelandic patients at baseline [median 3.1 (interquartile range 3.0-3.8) vs 2.3 (2.1-2.9) mg/kg, P < 0.05] and after 12 months [3.3 (3.0-4.5) vs 2.9 (2.2-3.5) mg/kg, P < 0.0001]. After 12 months, 58% of Danish and 66% of Icelandic patients maintained treatment. Danish patients had shorter drug survival than Icelandic patients (1183 vs 483 days). In univariate analyses stratified by country, time until dose escalation, response rates, drug survival and 1-year's disease activity were independent of starting dose. Drug survival was shorter among patients not receiving concomitant MTX.

CONCLUSION: In clinical practice, > 70% of Icelandic and Danish PsA patients treated with infliximab received sustained doses below the 5 mg/kg every 8 weeks recommended in international guidelines. Lower starting doses did not affect drug survival or response.

Original languageEnglish
JournalRheumatology
Volume53
Issue11
Pages (from-to)2100-9
Number of pages10
ISSN1462-0324
DOIs
Publication statusPublished - Nov 2014

    Research areas

  • Adult, Antibodies, Monoclonal/administration & dosage, Antirheumatic Agents/administration & dosage, Arthritis, Psoriatic/drug therapy, Dose-Response Relationship, Drug, Female, Follow-Up Studies, Humans, Infliximab, Infusions, Intravenous, Male, Middle Aged, Prospective Studies, Registries, Treatment Outcome, Tumor Necrosis Factor-alpha/antagonists & inhibitors

See relations at Aarhus University Citationformats

ID: 131003253